Related Experiment Video

Updated: May 12, 2025

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.4K

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications

Nyein Wint Yee Theik1, Suset Almuinas De Armas1, Daniel Rosas2

  • 1Memorial Healthcare System, Internal Medicine Residency Program, Pembroke Pines, FL 33028, USA.

International Journal of Molecular Sciences
|May 7, 2025
PubMed

Insights

Targeted therapies like tyrosine kinase inhibitors (TKIs) show promise for non-small cell lung cancer (NSCLC) driven by genetic fusions (ALK, ROS1, RET, NTRK). Research continues to address challenges like acquired mutations for improved NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is frequently driven by genetic alterations.
  • Oncogenic fusions, including ALK, ROS1, RET, and NTRK, play a crucial role in NSCLC tumorigenesis.
  • Chromosomal rearrangements leading to these fusions are key oncogenic drivers.

Purpose of the Study:

  • To review the role of oncogenic fusions in NSCLC.
  • To discuss the impact of targeted therapies, such as tyrosine kinase inhibitors (TKIs), on NSCLC treatment.
  • To highlight challenges and future research directions in NSCLC therapy.

Main Methods:

  • Literature review of studies on NSCLC genetic alterations and targeted therapies.
  • Analysis of common oncogenic fusions and their signaling pathways.
  • Evaluation of the efficacy and challenges of tyrosine kinase inhibitors (TKIs).

Main Results:

  • Oncogenic fusions are significant drivers in NSCLC, involving pathways like ALK, ROS1, RET, and NTRK.
  • Targeted therapies (TKIs) offer improved efficacy and tolerability over traditional chemotherapy for NSCLC patients.
  • Acquired mutations present a challenge, necessitating ongoing research for optimized NSCLC treatments.

Conclusions:

  • Targeted therapies targeting specific genetic fusions have transformed NSCLC treatment.
  • Understanding molecular drivers like oncogenic fusions is critical for personalized medicine in NSCLC.
  • Continued research is essential to overcome resistance mechanisms and improve long-term outcomes for NSCLC patients.
Keywords:
ALKNSCLCNTRKRETROS1TKImutationoncogenic driver

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

987

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K